Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Inclusion Criteria:

* Histologic or cytological diagnosis of inoperable locally advanced (stage III) NSCLC.
* No prior chemotherapy, immunotherapy, or radiotherapy.
* Performance status of 0 to 2 on the Zubrod scale.
* Clinically measurable disease, defined as bidimensionally measurable lesions with clearly defined margins on x-ray, scan, or physical examination. Lesions serving as measurable disease must be at least 1 cm by 1 cm, as defined by computerized tomography (CT) scan, magnetic resonance imaging (MRI), or chest x-ray.
* Estimated life expectancy of at least 12 weeks.
* Patient compliance and geographic proximity that allow adequate follow-up.
* Adequate bone marrow reserve: white blood cell (WBC) count \*4,000/mm3, platelets \>100,000/mm3, and hemoglobin \*10 g/dL.
* Informed consent from patient.
* Males or females 18 years of age or older.
* If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine contraceptive device \[IUD\], birth control pills, or barrier device) during and for three months after trial.

Exclusion Criteria:

* Active infection (at the discretion of the investigator).
* Inadequate liver function (total bilirubin \>1.5 times above normal range); alanine transaminase (ALT) and aspartate transaminase (AST) greater than 3 times normal (ALT and AST may be elevated to 5 times normal in patients with known metastatic disease in the liver).
* Inadequate renal function (creatinine \>2.0 mg/dL).
* Pregnancy or not using appropriate birth control during the study.
* Breast feeding.
* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
* Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)
* Use of any investigational agent in the month before enrollment into the study.
* Patients with leukemia and/or a secondary primary carcinoma except for patients who have had curative therapy to basal cell carcinoma.
* Concomitant myelosuppressive radiotherapy, chemotherapy, hormonal therapy, or immunotherapy will not be allowed except as previously noted for radiation.
* Active cardiac disease requiring therapy for failure, angina, and/or arrhythmias; infarctions within the preceding six months (exception: any patient whose cardiac failure is compensated on medications).